Plain-English translation of NCT05375370 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This research study is testing whether a blood test that detects circulating tumor DNA—tiny pieces of cancer DNA floating in your bloodstream—can help predict if your liver cancer will come back after surgery or other treatments. Researchers believe this blood test may catch early warning signs of recurrence before cancer becomes visible on standard imaging scans, giving doctors more time to intervene.
Liver cancer comes back in about one-third to one-half of patients within two years after successful surgery, even when the tumor appears to be completely removed. This study exists to see whether the new blood test could identify patients at highest risk of recurrence early enough to make a real difference in treatment decisions and outcomes.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will have blood samples drawn at specific time points after your surgery or treatment—these samples will be tested for circulating tumor DNA to see if tiny cancer cells are detectable. You'll continue regular follow-up visits at the hospital as part of your standard care, and researchers will track whether the blood test results help predict which patients develop recurrent cancer. The study involves no new medications or procedures beyond the blood draws that are part of routine monitoring.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
France
Sponsor
University Hospital, Rouen
Enrollment target
~150 participants
Started
August 2022
Primary completion
February 2029
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Edouard ROUSSEL, MD
University Hospital, Rouen
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.